Arca
Skip to content
Tools
Tools

Label Changes: Enflonsia (clesrovimab-cfor)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Enflonsia label DailyMed has published, from Merck Sharp & Dohme LLC, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 4
  • Sections changed, version 4 to 5: 5

What changed from version 4 to version 5

Oct 15, 2026 to Nov 5, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged ยท punctuation or symbols only
  2. Adverse reactionsChanged ยท 15 words added, 13 removed
  3. Clinical pharmacologyChanged ยท 2 words added, 1 removed
  4. Clinical studiesChanged ยท 2 words added, 1 removed
  5. Untitled sectionChanged ยท 2 words added, 2 removed

Indications and usage

Changedpunctuation or symbols only
1 INDICATIONS AND USAGE
ENFLONSIAโ„ข is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Adverse reactions

Changed15 words added, 13 removed
5 unchanged lines
Trial 004 was a Phase 2b/3, randomized, double-blind placebo-controlled, multisite trial conducted in early and moderate preterm infants (โ‰ฅ29 to <35 weeks gestational age (GA)) and late preterm and full-term infants (โ‰ฅ35 weeks GA). Participants were randomized 2:1 and received a single 105 mg dose of ENFLONSIA (N=2,412, including 422 early and moderate preterm infants) or saline placebo (N=1,202, including 209 early and moderate preterm infants) by IM injection. Participants were monitored for 30 minutes post-dose. Safety was assessed using an electronic diary device from Days 1 through 42 post-dose. Participants were monitored for serious adverse events (SAEs) through the duration of their participation for up to 365 days post-dose. A subset of participants was monitored for SAEs for up to 515 days post-dose.
Table 1 summarizes the adverse reactions in participants who received ENFLONSIA. Mostand most (โ‰ฅ97>94%) of the adverse reactionsthese were toxicity grade 1 (mild) or grade 2 (moderate).
Table 1: Adverse Reactions Reported at an Incidence HigherGreater Than or Equal to Placebo (Trial 004)
Adverse Reaction | ENFLONSIA N=2,412 % | Placebo N=1,202 %
Injection-site erythema (occurring within 5 days post-dose) | 34.85 | 3.36
Injection-site swelling (occurring within 5 days post-dose) | 23.72 | 23.62
Rash (occurring within 14 days post-dose) | 2.3 | 1.9
3 unchanged lines

Clinical pharmacology

Changed2 words added, 1 removed
1 unchanged line
12.1 Mechanism of Action
ENFLONSIA is a monoclonal antibody with anti-RSV activity [see MicrobiologyClinical Pharmacology (12.4)].
12.2 Pharmacodynamics
42 unchanged lines

Clinical studies

Changed2 words added, 1 removed
7 unchanged lines
Trial 007 (NCT04938830) | Infants born at โ‰ค35 weeks GA, or infants with CLD of prematurity or hemodynamically significant CHD from birth up to 1 year entering their first RSV season. | ENFLONSIA (N=446) Palivizumab (N=450)
14.2 Prevention of RSV-Associated Disease in Neonates and Infants (โ‰ฅ29 Weeks GAGestational Age) Entering Their First RSV Season (Trial 004)
Trial 004 was a Phase 2b/3, randomized, double-blind placebo-controlled, multi-site trial conducted in 22 countries from the Northern and Southern Hemispheres to evaluate the efficacy of ENFLONSIA in early and moderate preterm infants (โ‰ฅ29 to <35 weeks GA) and late preterm and full-term infants (โ‰ฅ35 weeks GA). The trial assessed the efficacy of ENFLONSIA in the prevention of RSV-associated disease across a spectrum of severity. Participants were randomized 2:1 to receive a single 105 mg dose of ENFLONSIA or saline placebo by IM injection.
13 unchanged lines

Untitled section

Changed2 words added, 2 removed
2 unchanged lines
For patent information: www.msd.com/research/patent
Copyright ยฉ 20252026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.
uspi-mk1654-i-2506r0012610r002

Unchanged: Dosage and administration, Dosage forms and strengths, Contraindications, Warnings and precautions, Drug interactions, Use in specific populations, Overdosage, Description, Nonclinical toxicology, How supplied, Patient counseling information, Patient information, PRINCIPAL DISPLAY PANEL - 1 Single-Dose Syringe Carton, PRINCIPAL DISPLAY PANEL - 10 Single-Dose Syringe Carton, PRINCIPAL DISPLAY PANEL - 0.7 mL Syringe Label.

Every version

4 versions of set c9004a92-40e8-4cdb-b22d-d07929f8fc3b, newest first.
VersionPublished on DailyMedCompareSPL file
5Nov 5, 2026Shown belowDownload .zip
4Oct 15, 2026With version 3Download .zip
3Jun 26, 2025With version 2Download .zip
2Jun 16, 2025First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.